It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.
Biointelect is a strategic planning and commercialisation firm for the biopharmaceutical and medical device sector including commercial, government and not-for-profit organisations.
Biointelect helps its clients develop and drive strategy, identify and evaluate new business opportunities and engage the right partners. The strategy consulting involves therapeutic development from start up through to post launch, with an Australian and a Global perspective.
Biointelect’s mission is to bring science to market.
Biocelect works with local and overseas partners to bring critical pharmaceutical products and medical technology solutions to the Australian market.
In addition to our travel range, infectious disease portfolio and novel medical diagnostics, Biocelect is the sponsor of the Novavax COVID-19 Vaccine, NVX-CoV2373 for Australia and New Zealand.
Biocelect’s mission is to build pathways to patients.
In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.
-
Global GP Conference comes to Australia
Over 3000 delegates from around the World will gather at the 50th celebration of WONCA to reconnect and revive General Practice, sharing knowledge and learnings on access, equity, funding, and multidisciplinary care teams. This includes networking with Australian and overseas GPs and in particular learning about primary care practices in other countries.
Australian Health Journal met with Dr Nicole Higgins, President of RACGP in transit at Brisbane Airport recently and she spoke about the $6 Billion allocated in the Federal Budget in May as a significant achievement for General Practice investment. She also emphasised this announcement reinforced GPs should be at the centre of multidisciplinary care teams to ensure continuity of care and better health outcomes.
-
Still seeking outcomes after 6th Stoma Appliance Scheme Schedule Review
50,000 Australians have undergone the trauma and challenge of having a stoma inserted. Whilst the Australian Government invests in the appliances and products they need through the Stoma Appliance Scheme (SAS), this list is dated and doesn’t include as many of the products available in other countries. A new report commissioned by the Stoma Industry Association (SIA) shows Australia lagging countries such as the United Kingdom, Canada and Spain in supporting ostomates (people with a stoma).
-
Mission to raise awareness of sarcoma and need for clinical trial funding
Sarcoma, a rare and aggressive cancer, remains the deadliest cancer for children and young adults, accounting for nearly one third (30%) of cancer-related deaths among those aged 15–24 and one tenth (10%) of those aged 0–14. Further, still severely under-diagnosed, sarcoma only accounts for one sixth (15%) of all cancer diagnoses in the 15 – 24 age group, and less than a tenth (8%) among children under 10.
